A new study out of Canada has found that a combination treatment of antibodies and virus-fighting proteins prevented death from Ebola-Zaire in some primates, even when administered three days after infection and when the early symptoms of the fever, which include fatigue and vomiting, begin to show. Thomas W. Geisbert, an expert on Ebola and siRNAs at UTMB, said the research was “highly significant because it shows protection against Ebola in a robust model of human disease: non-human primates.” His only concern, he said, was to with the nature of the virus used in the study. This article was originally published in The Conversation. The news also appears in the Toronto Star, among other outlets.